Latest On Merrimack Pharmaceuticals, Inc (MACK):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 02:53 EST | News | Merrimack Pharmaceuticals GAAP EPS of $0.02 | N/A |  |
| 2023-03-09 19:03 EST | News | Merrimack Pharmaceuticals GAAP EPS of -$0.11 | N/A | |
| 2023-01-04 21:18 EST | News | Merrimack Still Has Significant Arbitrage Potential | N/A | |
| 2022-11-09 08:17 EST | News | Merrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goal | N/A | |
| 2022-11-04 05:04 EST | News | Merrimack Pharmaceuticals GAAP EPS of -$0.03 | N/A | |
About Merrimack Pharmaceuticals, Inc (MACK):
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
General
- Name Merrimack Pharmaceuticals, Inc
- Symbol MACK
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1271:1000
- Last Split Date2019-09-06
- Fiscal Year EndDecember
- IPO Date2012-03-29
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.merrimack.com
Valuation
- Trailing PE 65.1
- Price/Book (Most Recent Quarter) 5.48
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -17%
- Return on Equity -18%
- Earnings Per Share $0.10
- Revenue Per Share $0
- Gross Profit -9100000
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 93.24 million
- EBITDA 134000
- PEG Ratio 0.07
- Analyst Target Price $4
- Book Value Per Share $1.20
Share Statistics
- Shares Outstanding 13.41 million
- Shares Float 8.11 million
- % Held by Insiders 324%
- % Held by Institutions 60.31%
- Shares Short 576520
- Shares Short Prior Month 589421
- Short Ratio 4.24
- Short % of Float 5%
- Short % of Shares Outstanding 4%
Technicals
- Beta 2.48
- 52 Week High $9.35
- 52 Week Low $1.49
- 50 Day Moving Average 7.2
- 200 Day Moving Average 5.64
Dividends
- Forward Annual Dividend Yield 57.71%
- Dividend Date 2019-12-23
- ExDividend Date 2019-12-13
- Dividend Per Share $1.5
- Dividend Yield 0%
Merrimack Pharmaceuticals, Inc (MACK) Dividend Calendar:
MACK's last dividend payment was made to shareholders on December 23, 2019.
Merrimack Pharmaceuticals, Inc (MACK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Merrimack Pharmaceuticals, Inc (MACK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Merrimack Pharmaceuticals, Inc (MACK) Chart:
Merrimack Pharmaceuticals, Inc (MACK) News:
Below you will find a list of latest news for Merrimack Pharmaceuticals, Inc (MACK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Merrimack Pharmaceuticals, Inc (MACK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Merrimack Pharmaceuticals, Inc (MACK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 8-K (Current report) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-27 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-07-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-24 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-05-28 | 8-K (Current report) | |
| 2020-05-28 | 8-K (Current report) | |
| 2020-05-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-04-22 | 4 (Statement of changes in beneficial ownership of securities) | |
Merrimack Pharmaceuticals, Inc (MACK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Merrimack Pharmaceuticals, Inc (MACK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 324%
Institutional Ownership: 6031%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-13 | Noah G. Levy | Director | Buy | 254.00 | 3.50 | 889.00 | 587,459.00 | |
| 2020-08-13 | Noah G. Levy | Director | Buy | 354.00 | 3.50 | 1,239.00 | 806,071.00 | |
| 2020-08-13 | Eric Andersen | Director | Buy | 609.00 | 3.50 | 2,131.50 | 820,055.00 | |
| 2020-08-12 | Eric Andersen | Director | Buy | 2,000.00 | 3.49 | 6,986.00 | 243,212.00 | |
| 2020-08-12 | Noah G. Levy | Director | Buy | 834.00 | 3.49 | 2,913.16 | 587,205.00 | |
| 2020-08-12 | Noah G. Levy | Director | Buy | 1,166.00 | 3.49 | 4,072.84 | 805,717.00 | |
| 2020-08-11 | Eric Andersen | Director | Buy | 14,030.00 | 3.45 | 48,437.17 | 241,212.00 | |
| 2020-08-11 | Noah G. Levy | Director | Buy | 5,856.00 | 3.45 | 20,217.84 | 586,371.00 | |
| 2020-08-11 | Noah G. Levy | Director | Buy | 8,186.00 | 3.45 | 28,262.17 | 804,551.00 | |
| 2020-07-22 | GARY L CROCKER | Officer | Sell | 5,986.00 | 3.04 | 18,208.81 | 0.00 | |
| 2020-07-22 | GARY L CROCKER | Officer | Sell | 17,000.00 | 3.20 | 54,434.00 | 0.00 | |
| 2020-07-22 | Eric Andersen | Director | Buy | 17,404.00 | 3.20 | 55,727.61 | 193,990.00 | |
| 2020-07-22 | Eric Andersen | Director | Buy | 33,192.00 | 3.04 | 100,966.74 | 227,182.00 | |
| 2020-07-22 | Noah G. Levy | Director | Buy | 33,435.00 | 3.20 | 107,058.87 | 540,027.00 | |
| 2020-07-22 | Noah G. Levy | Director | Buy | 40,488.00 | 3.04 | 123,160.45 | 580,515.00 | |
| 2020-07-22 | Noah G. Levy | Director | Buy | 46,745.00 | 3.20 | 149,677.49 | 739,759.00 | |
| 2020-07-22 | Eric Andersen | Director | Buy | 62,775.00 | 3.20 | 201,005.55 | 755,543.00 | |
| 2020-07-22 | Noah G. Levy | Director | Buy | 56,606.00 | 3.04 | 172,189.79 | 796,365.00 | |
| 2020-07-22 | Eric Andersen | Director | Buy | 63,903.00 | 3.04 | 194,386.54 | 819,446.00 | |
| 2020-04-21 | Noah G. Levy | Director | Buy | 591.00 | 3.25 | 1,920.75 | 506,592.00 | |